Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease

被引：1

作者：

Marras, Connie ^{[1
,2
]}

Mills, Kelly A. ^{[3
]}

Eberly, Shirley ^{[4
]}

Oakes, David ^{[4
]}

Chou, Kelvin L. ^{[5
,6
]}

Halverson, Matthew ^{[7
]}

Parashos, Sotirios A. ^{[8
]}

Tarolli, Christopher G. ^{[9
]}

Lai, Jin-Shei ^{[10
]}

Nowinsky, Cindy J. ^{[10
,11
]}

Suchowersky, Oksana ^{[12
]}

Farbman, Eric S. ^{[13
]}

Shulman, Lisa M. ^{[14
]}

Simuni, Tanya ^{[11
]}

机构：

[1] Univ Toronto, Toronto Western Hosp, Edmond J Safra Program Parkinsons Res, Toronto, ON, Canada

[2] Univ Toronto, Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON, Canada

[3] Johns Hopkins Univ, Johns Hopkins Parkinsons Dis & Movement Disorders, Baltimore, MD USA

[4] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA

[5] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA

[6] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA

[7] Univ Utah, Salt Lake City, UT USA

[8] Pk Nicollet Hlth Serv, Struthers Parkinsons Ctr, Golden Valley, MN USA

[9] Univ Rochester, Dept Neurol, Rochester, NY USA

[10] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA

[11] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA

[12] Univ Alberta, Dept Med Neurol Med Genet & Pediat, Edmonton, AB, Canada

[13] Roseman Univ Hlth Sci, Dept Neurol, Las Vegas, NV USA

[14] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA

来源：

MOVEMENT DISORDERS | 2021年 / 36卷 / 08期

关键词：

quality of life; measurement; Parkinson' s disease; Neuro‐ QoL; RESPONSE SHIFT; DISABILITY; TRIAL;

D O I：

10.1002/mds.28641

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background The Quality of Life in Neurological Disorders (Neuro-QoL) is a publicly available health-related quality-of-life measurement system. Objective The aim of this study was to evaluate the utility of Neuro-QoL item banks as outcome measures for clinical trials in Parkinson's disease. Methods An analysis of Neuro-QoL responsiveness to change and construct validity was performed in a multicenter clinical trial cohort. Results Among 310 participants over 3 years, changes in five of eight Neuro-QoL domains were significant (P < 0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35-0.39). The largest effect size for change over the year in which levodopa was initiated was -0.19 for lower extremity function-mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to more than 1000 participants per group. Conclusions More sensitive tools will be required to serve as an outcome measure in early Parkinson's disease. (c) 2021 International Parkinson and Movement Disorder Society

引用

页码：1979 / 1983

页数：5

共 19 条

[1] [Anonymous], 2009, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
[2] Neuroprotection in Parkinson's disease: An elusive goal
Biglan, Kevin M.
Ravina, Bernard
[J]. SEMINARS IN NEUROLOGY, 2007, 27 (02) : 106 - 112
[3] A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)
Biglan, Kevin M.
Oakes, David
Lang, Anthony E.
Hauser, Robert A.
Hodgeman, Karen
Greco, Brittany
Lowell, Jillian
Rockhill, Rebecca
Shoulson, Ira
Venuto, Charles
Young, Diony
Simuni, Tanya
[J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (06): : 360 - 368
[4] Neuro-QOL Brief measures of health-related quality of life for clinical research in neurology
Cella, D.
Lai, J-S.
Nowinski, C. J.
Victorson, D.
Peterman, A.
Miller, D.
Bethoux, F.
Heinemann, A.
Rubin, S.
Cavazos, J. E.
Reder, A. T.
Sufit, R.
Simuni, T.
Holmes, G. L.
Siderowf, A.
Wojna, V.
Bode, R.
McKinney, N.
Podrabsky, T.
Wortman, K.
Choi, S.
Gershon, R.
Rothrock, N.
Moy, C.
[J]. NEUROLOGY, 2012, 78 (23) : 1860 - 1867
[5] Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan
Goetz, Christopher G.
Fahn, Stanley
Martinez-Martin, Pablo
Poewe, Werner
Sampaio, Cristina
Stebbins, Glenn T.
Stern, Matthew B.
Tilley, Barbara C.
Dodel, Richard
Dubois, Bruno
Holloway, Robert
Jankovic, Joseph
Kulisevsky, Jaime
Lang, Anthony E.
Lees, Andrew
Leurgans, Sue
LeWitt, Peter A.
Nyenhuis, David
Olanow, C. Warren
Rascol, Olivier
Schrag, Anette
Teresi, Jeanne A.
van Hilten, Jacobus J.
LaPelle, Nancy
[J]. MOVEMENT DISORDERS, 2007, 22 (01) : 41 - 47
[6] Clinical trial end points - On the road to nowhere?
Holloway, RG
Dick, AW
[J]. NEUROLOGY, 2002, 58 (05) : 679 - 686
[7] Disease-Modifying Strategies for Parkinson's Disease
Kalia, Lorraine V.
Kalia, Suneil K.
Lang, Anthony E.
[J]. MOVEMENT DISORDERS, 2015, 30 (11) : 1442 - 1450
[8] Evaluating Individual Change With the Quality of Life in Neurological Disorders (Neuro-QoL) Short Forms
Kozlowski, Allan J.
Cella, David
Nitsch, Kristian P.
Heinemann, Allen W.
[J]. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2016, 97 (04): : 650 - 654
[9] Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson's disease
Lamichhane, Dronacharya
Gruber-Baldini, Ann L.
Reich, Stephen G.
Shulman, Lisa M.
[J]. QUALITY OF LIFE RESEARCH, 2016, 25 (12) : 3139 - 3145
[10] Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations
Martinez-Martin, Pablo
Jeukens-Visser, Martine
Lyons, Kelly E.
Rodriguez-Blazquez, C.
Selai, Caroline
Siderowf, Andrew
Welsh, Mickie
Poewe, Werner
Rascol, Oliver
Sampaio, Cristina
Stebbins, Glenn T.
Goetz, Christopher G.
Schrag, Anette
[J]. MOVEMENT DISORDERS, 2011, 26 (13) : 2371 - 2380

← 1 2 →